Cite
HARVARD Citation
Silla, L. et al. (2021). Adoptive immunotherapy with double‐bright (CD56bright/CD16bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concept study. British journal of haematology. pp. 710-721. [Online].